scispace - formally typeset
Search or ask a question

Showing papers on "Doxorubicin published in 1977"


Journal ArticleDOI
TL;DR: Doxorubicin hydrochloride (Adriamycin) therapy was associated with renal failure in a 78-year-old man, and Renal function should be monitored in patients receiving doxorUBicin.
Abstract: Doxorubicin hydrochloride (Adriamycin) therapy was associated with renal failure in a 78-year-old man. The pathophysiologic findings in this patient were similar to those seen following administration of structural analogues of doxorubicin. Daunorubicin hydrochloride, particularly, is known to cause renal failure in experimental animals. Renal function should be monitored in patients receiving doxorubicin. (Arch Intern Med137:385-388, 1977)

75 citations


Journal ArticleDOI
TL;DR: The favorable response of this tumor to doxorubicin suggests that both postoperative irradiation and chemotherapy should be used in its treatment.
Abstract: Postoperative radiation therapy was given for medullary carcinoma of the thyroid in 5 patients. Moderately high doses of radiation achieved local control. Four patients died of metastatic disease. The favorable response of this tumor to doxorubicin suggests that both postoperative irradiation and chemotherapy should be used in its treatment.

49 citations


Journal Article
TL;DR: Mitomycin C, doxorubicin, methotrexate, and 5-fluorouracil appear to have cytotoxic activity against bladder carcinoma when used as single agents, although the reported objective responses to each agent vary greatly.
Abstract: This paper is a summary of the clinical chemotherapy of metastatic or recurrent bladder carcinoma. Mitomycin C, doxorubicin, methotrexate, and 5-fluorouracil appear to have cytotoxic activity against bladder carcinoma when used as single agents, although the reported objective responses to each agent vary greatly. Cyclophosphamide in intermittent high i.v. doses produced an objective response in 4 of 10 patients treated by the author, and other reports suggest that this drug also may have activity against bladder cancer. cis -Dichlorodiammineplatinum is a new drug that also deserves further study

37 citations


Journal ArticleDOI
TL;DR: Seven patients with metastatic tumors resistant to therapy with adriamycin, BCNU, plus cyclophosphamide received the same chemotherapy combined with amphotericin B, reverses resistance to adRIamycin-containing chemotherapy regimens in some patients.
Abstract: Seven patients with metastatic tumors resistant to therapy with adriamycin, BCNU, plus cyclophosphamide received the same chemotherapy combined with amphotericin B. One complete response (...

36 citations


Journal ArticleDOI
TL;DR: Doxorubicin hydrochloride (Adriamycin), an anthracycline antibiotic that has a broad spectrum of antitumor activity, has been widely used as a single agent or in combination with other drugs.
Abstract: To the Editor.— Doxorubicin hydrochloride (Adriamycin), an anthracycline antibiotic that has a broad spectrum of antitumor activity, has been widely used as a single agent or in combination with other drugs. 1 The major toxic side effects have been nausea, vomiting, mucosal ulcerations, alopecia, hematopoietic depression, and cardiomyopathy. I would like to report two unusual melanotic cutaneous reactions related to doxorubicin therapy. Fig 1.—Black hyperpigmentation on palm. Fig 2.—Black hyperpigmentation on nails and nailbeds. Report of Cases.—Case 1.— A 55-year-old black woman was referred for chemotherapy for metastatic breast carcinoma. In November 1973, she underwent radical mastectomy for carcinoma of the left breast, with an uneventful recovery. In May 1974, an epidural metastasis developed, with compression of the spinal cord at the T-4 and T-5 levels. Laminectomy was performed and she was subsequently treated with cyclophosphamide (Cytoxan), methotrexate, vincristine sulfate, fluorouracil, and prednisone. 2 After further progression, with an appearance

17 citations




Journal ArticleDOI
01 Dec 1977-BJUI
TL;DR: 18 patients with category T3 bladder cancer were treated with a combination of radical radiotherapy followed after an interval of 1-3 months by pulsed chemotherapy with adriamycin and 5-fluorouracil, finding the regime was well tolerated.
Abstract: 18 patients with category T3 bladder cancer were treated with a combination of radical radiotherapy followed after an interval of 1-3 months by pulsed chemotherapy with adriamycin and 5-fluorouracil. Providing the chemotherapy was limited to 4 cycles, there was no serious toxicity and the regime was well tolerated.

10 citations







Journal ArticleDOI
TL;DR: The treatment safety and resultant increased longevity were not enhanced by single-dose chemotherapy with doxorubicin and/or dacarbazine, and suggests that additive or potentiated effects follow the two-parameter procedure.

Journal ArticleDOI
TL;DR: Combination effect of agents was affected by the schedule of drug administration for doxorubicin, but weak for daunorubICin, and combination of a larger number of agents in simultaneous administration provided antagonism compared with an alternate administration.
Abstract: Combination effect of antitumor agents, including doxorubicin and daunorubicin, was evaluated on the concept of pharmacological synergism in ascites sarcoma-180 system. In alternate adminsitration, combinations of doxorubicin plus cyclophosphamide, thio-TEPA, carboquone, actinomycin-D, vinblastine, vincristine, methotrexate, cytarabine, 6-mercaptopurine, or L-asparaginase showed synergism, but in simultaneous one, only three agents, cyclophosphamide, carboquone, and cytarabine, were synergistic. On the other hand, combination of daunorubicin plus one of 8 agents (thio-TEPA, mitomycin-C, bleomycin, actinomycin-D, vinblastine, ancytabine, 6-mercaptopurine, and L-asparaginase) and 6 agents (cyclophosphamide, thio-TEPA, mitomycin-C, bleomycin, actinomycin-D, and vinblastine) provided synergism in alternate and simultaneous administration. Combination effect of agents was affected by the schedule of drug administration for doxorubicin, but weak for daunorubicin. Toxicity of doxorubicin or daunorubicin in combination with other drugs was also affected by the schedule of administration. Combination of a larger number of agents in simultaneous administration provided antagonism compared with an alternate administration.